Showing 651-660 of 822 results for "".
Patient-Centric Innovations in MS Care: High-Efficacy DMTs, Cognition, and Special Patient Populations
https://practicalneurology.com/programs/cme/patient-centric-innovations-in-ms-care-high-efficacy-dmts-cognition-and-special-patient-populations/29171/Tune in to learn more about the use of high-efficacy DMTs in multiple sclerosis.- From Classroom to Clinic: The Multiple Guises of Motor Neuron Diseasehttps://practicalneurology.com/diseases-diagnoses/movement-disorders/pn0807-motor-neuron-disease-pdf/31136/In the August 2007 issue of *Practical Neurology*, Dr. Leo McCluskey presents a series of intricate case studies focused on Motor Neuron Disease (MND), particularly emphasizing atypical presentations of Amyotrophic Lateral Sclerosis (ALS). These real-world scenarios are crafted to challenge and enha
- Will Generics Gobble Up The Neurology Market?https://practicalneurology.com/columns/practice-management/will-generics-gobble-up-the-neurology-market/31082/Generics Gain Ground in Neurology: Implications for Clinical PracticeThe landscape of neurology pharmacotherapy is shifting as generic medications increasingly replace brand-name drugs, promising substantial cost savings without compromising efficacy. As highlighted in the December 2007 issue of *Pr
- Pain Managementhttps://practicalneurology.com/diseases-diagnoses/headache-pain/pn0807-pain-mngmnt-pdf/31138/In the inaugural part of a two-part series, Dr. Charles Argoff explores the intricate relationship between neuropathic pain, sleep disturbances, and psychiatric disorders such as depression and anxiety. Neuropathic pain, arising from lesions or dysfunctions within the peripheral or central nervous s
- Tackling the Challenges of Advanced Parkinson's Diseasehttps://practicalneurology.com/diseases-diagnoses/movement-disorders/pn1206parkinsonsfea-pdf/31241/Advanced Parkinson’s Disease: Clinical Challenges and Management StrategiesParkinson’s disease (PD) in its advanced stages presents a complex clinical landscape, extending beyond the classic motor symptoms of bradykinesia, rigidity, and tremor. While levodopa has significantly mitigated these primar
- Advancements in Epilepsy Syndrome Diagnosis and Managementhttps://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/pn0208-epilepsy-dept-pdf/31051/Advancements in Epilepsy Syndrome Diagnosis and ManagementEpilepsy, one of the most historically recognized neurological disorders, remains the second most prevalent neurological condition, affecting approximately one percent of the global population. In the United States and Europe, new epilepsy ca
- Editor's Messagehttps://practicalneurology.com/columns/practice-management/editors-message/31077/In the December 2007 issue of Practical Neurology, Editor-in-Chief Jack Persico draws a poignant parallel between the classic film "It's a Wonderful Life" and the current state of neurology practice. Highlighting an article by Dr. Ronald DeVere, the discussion focuses on the pervasive issue of physi
- Pain Managementhttps://practicalneurology.com/diseases-diagnoses/headache-pain/pn0207-painmngmnt-pdf/31219/Chronic Pain Prevalence Among US Workers: Implications for NeurologistsRecent findings highlight a growing prevalence of chronic pain among American workers, significantly impacting productivity and quality of life. A 2006 survey conducted by Harris Interactive, encompassing 1,103 US adult workers a
- Vascular Clinichttps://practicalneurology.com/columns/practice-management/vascular-clinic/31404/Enhancing TIA Management with the ABCD Scoring SystemTransient ischemic attacks (TIAs) present a critical challenge in neurology due to their transient nature and the imperative decision of inpatient versus outpatient management. Historically, the lack of standardized clinical guidelines has resulte
- News Briefshttps://practicalneurology.com/columns/practice-management/news-briefs/31495/Advancements in Alzheimer’s Disease Detection and TreatmentRecent strides in Alzheimer’s disease (AD) research offer promising avenues for early detection and potential treatment options, as highlighted in the latest findings shared by leading institutions. While a definitive biomarker for AD remain